ProQR Therapeutics (PRQR) Liabilities and Shareholders Equity (2021 - 2025)

ProQR Therapeutics' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $179.5 million for Q4 2024.

  • For Q4 2024, Liabilities and Shareholders Equity rose 20.98% year-over-year to $179.5 million; the TTM value through Dec 2024 reached $742.4 million, changed N/A, while the annual FY2024 figure was $181.8 million, 21.88% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2024 was $179.5 million at ProQR Therapeutics, up from $148.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $239.8 million in Q4 2021 and bottomed at $148.4 million in Q4 2023.
  • The 4-year median for Liabilities and Shareholders Equity is $177.1 million (2022), against an average of $185.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity fell 27.1% in 2022 before it rose 20.98% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $239.8 million in 2021, then fell by 27.1% to $174.8 million in 2022, then fell by 15.12% to $148.4 million in 2023, then grew by 20.98% to $179.5 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Liabilities and Shareholders Equity are $179.5 million (Q4 2024), $148.4 million (Q4 2023), and $174.8 million (Q4 2022).